Navigation Links
Adamis Pharmaceuticals CEO Provides Update for Shareholders
Date:5/3/2013

ur Beclomethasone-HFA product to initiate Phase III studies in asthma and COPD
  • Finalizing our allergic rhinitis product development in order to initiate Phase III clinical trials
  • Acquiring or in-licensing an established product or technology that, following regulatory marketing approvals, will compete in large (multi-billion dollar) product markets and will be synergistic with our existing assets.
  • On the Biotech side, we are focused on:

    • Completing our Phase I prostate cancer drug trial
    • Finalizing the activities necessary to begin a Phase I/II trial for our second prostate compound
    • Initiating a Phase II prostate cancer vaccine trial for TeloB-VAX.

    If we are able to complete additional financing transactions and make progress on our objectives, we intend to take the necessary steps to be in a position to list our common stock on a national stock exchange such as the NYSE-Amex or NASDAQ.  An up-listing could lead to an increase in shareholder value, give Adamis more market exposure, increase liquidity and partnering activities and increase our shareholder base to include more fundamental health care investors.

    I would like to thank all of our shareholders for their continued support and patience.  We will all do our very best to make Adamis a company that you will all be very proud of owning.

    Best regards,

    Dennis J. Carlo , Ph.D
    President and CEO

    About Adamis Pharmaceuticals Corporation

    Adamis Pharmaceuticals Corporation is a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology and immunology.  Products in its specialty pharmaceutical pipeline include the Epinephrine Injection PFS syringe for use in the emergency treatment of a
    '/>"/>

    SOURCE Adamis Pharmaceuticals Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related biology technology :

    1. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
    2. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
    3. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
    4. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
    5. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
    6. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
    7. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
    8. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
    9. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
    10. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results
    11. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... 15, 2014 AudioNotch is the internet's ... for the treatment of tinnitus. Patients listen to sound ... over a period of weeks to months, their tinnitus volume ... two forms: Notched Music and Notched White Noise. Now, AudioNotch ...
    (Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of ... regulatory, business, and media events in the United States ... former associate Virginia Cox , JD, is returning to the ... Virginia Cox re-joins 3D after more than two years of ...
    (Date:1/14/2014)... iLab Solutions, the leader in core facility management ... Product Strategy. In this role, Michelle will work with current ... in the development of iLab products. Her main goal will ... to the scientific community by offering the most advanced, user-friendly, ...
    (Date:1/14/2014)... 13, 2014 Bob Hainsey, a semiconductor ... 20 years in the industry, has joined SPIE, ... will serve as the society’s Science and Technology Strategist. ... SPIE as our Technology Strategist, further strengthening the technical ...
    Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
    ... the impact of one of the fastest growing eye diseases on ... provide physicians with a virtual experience of having neovascular (wet) age-related ... ... January 29, 2009 -- To help eye specialists better understand the ...
    ... a leader in renewable energy and biofuels development and production, today announced ... of the Board of Directors. , ... Los Angeles (PRWEB) January 29, ... and production, today announced the appointment of David Pyrce as its Chief ...
    ... CHADDS FORD, Pa., Jan. 28 Endo Pharmaceuticals Inc. ... quarter and 2008 full-year financial results on February 27, ... webcast at 10:30 a.m. ET that day to discuss ... Executive Officer, Nancy J. Wysenski, Chief Operating Officer and ...
    Cached Biology Technology:Looking at AMD Through Patients' Eyes: Viscira Virtual Exhibit Educates Physicians by Personalizing Serious Eye Disease 2Looking at AMD Through Patients' Eyes: Viscira Virtual Exhibit Educates Physicians by Personalizing Serious Eye Disease 3Nexsun Corp Names Industry Executive David Pyrce as Chief Executive Officer 2Endo Pharmaceuticals to Announce Fourth Quarter and 2008 Full-Year Financial Results on February 27, 2009 2
    (Date:4/17/2014)... German . Our ... provide us with a continuous stream of information about our ... still in a car the world glides by us ... without effort, our brain calculates self-motion from this "optic flow". ... steady gaze during our own movements. Together with biologists from ...
    (Date:4/17/2014)... Stem cells in bone marrow need to produce hydrogen ... tissue, according to a new study from the Center ... of Dentistry of USC. , Professor Songtao Shi, principal ... sulfide produced by the cells governs the flow of ... cellular signals that results in osteogenesis, or the creation ...
    (Date:4/17/2014)... The White House honored Clemson professor Rajendra Singh ... efforts to promote and expand solar deployment in ... the D. Houser Banks Professor of Electrical and ... Silicon Nanoelectronics, is considered a local hero leading ... and economic opportunity in solar power and driving ...
    Breaking Biology News(10 mins):How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4White House honors Clemson professor as 'Champion of Change' for solar deployment 2
    ... cholera that has sickened thousands in Haiti came from a ... over the past three years as some have thought, according ... online open-access journal of the American Society for Microbiology. ... earlier findings that indicate Vibrio cholerae bacteria were ...
    ... 2013 New materials and potential new drug targets are ... major scientific meeting on the structure of molecules. More information ... in mid-July. The Annual Meeting of the American Crystallographic ... at the Sheraton Waikiki Beach Hotel in Honolulu, Hawaii. Crystallography ...
    ... The Fondation Leducq in Paris, France, dedicated to improving ... awarded a $6 million grant award to a new ... researchers from the Cardiovascular Research Center at Icahn School ... large grant was awarded as part of the Fondation ...
    Cached Biology News:Genomes of cholera bacteria from Haiti confirm epidemic originated from single source 2Genomes of cholera bacteria from Haiti confirm epidemic originated from single source 3New materials, progress toward an HIV vaccine, and more at meeting of crystallographers 2New materials, progress toward an HIV vaccine, and more at meeting of crystallographers 3Fondation Leducq awards $6 million grant for global research network for cardiac regeneration 2Fondation Leducq awards $6 million grant for global research network for cardiac regeneration 3
    Human HVEM/TNFRSF14 Allophycocyanin MAb (Clone 94801)...
    Enodgenous alkaline phosphotase inhibitor. Levamisole solution is supplied in concentrated form (20x). The final concentration of levamisole in the substrate solution will be 1 mM....
    X-gal,1g...
    ...
    Biology Products: